
|Videos|January 13, 2014
The Utility of TH-302 in Sarcoma
Author(s)Vicki Keedy, MD
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.
Advertisement
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.
Clinical Pearls:
- TH-302 is similar to ifosfamide but is a hypoxia-induced agent
- TH-302 targets the large areas of hypoxia found in sarcomas that chemotherapy cannot reach
- A randomized phase III study of Adriamycin (doxorubicin) versus Adriamycin plus TH-302 is undergoing accrual
- The initial phase II data is promising with good progression-free survival data
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































